The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR study and also around the definition of sustained remission in this study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR.’ (Abstract number: 1543) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is sarilumab and what is the rationale for its use in the treatment of glucocorticoid (GC) resistant polymyalgia rheumatica (PMR)? (0:15)
- What were the aims, design and inclusion criteria of the SAPHYR study? (1:30)
- What was the definition of sustained remission in this study? (3:03)
- What were the findings of the study? (3:42)
Disclosures: Robert Spiera discloses consulting for GSK, Regeneron, Abbvie, Sanofi, Chemocentryx, Novartis, Galderma, Vera Chemomab, Boehringer Ingelheim, and BMS; grant/ research support from Roche-Genetech, Astra-Zeneca, GSK, Kadmon, Boehringer Ingelheim, Chemocentryx, Corbus, Formation Biologics, Novartis, Inflarx, and Principia; and honoraria from GSK, Regeneron, Abbvie, Sanofi, Chemocentryx, Novartis, Galderma, Vera Chemomab, Boehringer Ingelheim, and BMS.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
